Pharmaceutical composition and method for enhancing solubility of poorly soluble active pharmaceutical ingredients
AssigneeMerck Patent GmbH
InventorsThomas KIPPING, Jonas LINDH, Julian QUODBACH
Life of this patent
Estimating the term…
Loading patent…
AssigneeMerck Patent GmbH
InventorsThomas KIPPING, Jonas LINDH, Julian QUODBACH
Estimating the term…
The present disclosure generally relates to the use of poloxamer in additive manufacturing technologies and techniques. More specifically, the present disclosure relates to the use of poloxamer in a selective laser sintering (SLS) method to additively manufacture an object, in particular a pharmaceutical dosage form. Also described is a process for selective laser sintering a sinter powder to form a pharmaceutical dosage form, in which the sinter powder includes at least one active pharmaceutical ingredient and at least one poloxamer with a melting point of 20° C. or higher.
A process for selective laser sintering of sinter powder to form a pharmaceutical dosage form, comprising sintering a sinter powder comprising at least one active pharmaceutical ingredient and at least one poloxamer with a melting point of 20° C. or higher.
A process for producing a pharmaceutical dosage form by selective laser sintering of sinter powder, comprising:
A sinter powder for selective laser sintering, comprising at least one active pharmaceutical ingredient and at least one poloxamer having a melting point of 20° C. or higher.
Dependencies are inferred from the claim text.